From Approval to Coverage – FDA and CMS Jurisdictional Lines
Recorded September 27, 2018 | On-Demand Webinar
When Markets Fail: Patents and Infectious Disease Products (Open Access)
Food and Drug Law Journal | Volume 73 | Number 3
Buying and Selling Prioritized Regulatory Review: The Market for Priority Review Vouchers as Quasi-Intellectual Property (Open Access) GalleryBuying and Selling Prioritized Regulatory Review: The Market for Priority Review Vouchers as Quasi-Intellectual Property (Open Access)
Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Journal 73.3, Publications
Buying and Selling Prioritized Regulatory Review: The Market for Priority Review Vouchers as Quasi-Intellectual Property (Open Access)
Food and Drug Law Journal | Volume 73 | Number 3
- Obsolete to Useful to Obsolete Once Again: A History of Section 507 of the Food, Drug, and Cosmetic Act Gallery
Obsolete to Useful to Obsolete Once Again: A History of Section 507 of the Food, Drug, and Cosmetic Act
Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Journal 73.3, Publications
Obsolete to Useful to Obsolete Once Again: A History of Section 507 of the Food, Drug, and Cosmetic Act
Food and Drug Law Journal | Volume 73 | Number 3
Facilitating Competition and Innovation Isn’t Easy: FDA’s Latest Hearing On Biologics
Update Magazine Extra
Guidance on Guidance: FDA, DOJ, and Enforcement
Recorded August 21, 2018 | On-Demand Webinar
Real World Evidence: Implications and Challenges for Medical Product Communications in an Evolving Regulatory Landscape GalleryReal World Evidence: Implications and Challenges for Medical Product Communications in an Evolving Regulatory Landscape
Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update August/September 2018, Update Magazine
Real World Evidence: Implications and Challenges for Medical Product Communications in an Evolving Regulatory Landscape
Update Magazine | August/September 2018
FDA’s Historical Use of “Real World Evidence”
Update Magazine | August/September 2018
For FDA, Addressing Drug Pricing Is a Matter of Doing Its Job Better
Update Magazine | August/September 2018
The DEA Quota System
Update Magazine | August/September 2018
